XNCR Xencor, Inc.

34.541.99 (+6.11%)
Close: June 18, 2019

Quote

Previous Close
$34.54
Day Range
$32.76-$34.65
52 Week Range
$27.75-$48.38
Volume
264,894
Avg Volume
206,603
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$1.95B
Enterprise Value (EV)
$1.54B
PE Ratio
49.74
EV/EBITDA
-20.31
Price/Sales
-
Price/Book
3.73
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$75.92M
EPS, ttm
$0.69
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/5/2019 (47 days)
Debt to Equity
-
Debt
-
Cash
$292.06M
Net Debt
-

Performance

Beta
1.66
200 Day Moving Avg
$35.07
50 Day Moving Avg
$32.15
52 Week Change
-18.05%
YTD Change
-2.94%
1 Month Change
-0.79%
3 Month Change
7.00%
6 Month Change
-4.82%
1 Year Change
-18.05%
2 Year Change
39.37%
5 Year Change
278.65%

Share Count

Shares Outstanding
56.4M
Float
55.6M
Restricted Shares
739.1K
Restricted Shares, %
1.31%

Xencor, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Bassil I. Dahiyat

Website: http://www.xencor.com

Description: Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Employees: 156